Document Type
Article
Publication Date
5-1-2025
Original Citation
Anthi A,
Kolderup A,
Vaage E,
Bern M,
Benjakul S,
Tjärnhage E,
Ruso-Julve F,
Jensen K,
Lode H,
Vaysburd M,
Nilsen J,
Herigstad M,
Sakya S,
Tietze L,
Pilati D,
Nyquist-Andersen M,
Dürkoop M,
Gjølberg T,
Peng L,
Foss S,
Moe M,
Low BE,
Wiles MV,
Nemazee D,
Jahnsen F,
Vaage J,
Howard K,
Sandlie I,
James L,
Grødeland G,
Lund-Johansen F,
Andersen J.
An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models. Nat Commun. 2025;16(1):3999.
Keywords
JMG, Animals, Administration, Intranasal, Mice, Immunity, Mucosal, Antibodies, Viral, SARS-CoV-2, Vaccines, Subunit, COVID-19, Female, COVID-19 Vaccines, Humans, Influenza A virus, Disease Models, Animal, Influenza Vaccines, Immunoglobulin A, Receptors, Fc, Mice, Transgenic, Orthomyxoviridae Infections, Mice, Inbred C57BL, Albumins, mRNA Vaccines, Histocompatibility Antigens Class I
JAX Source
Nat Commun. 2025;16(1):3999.
ISSN
2041-1723
PMID
40312392
DOI
https://doi.org/10.1038/s41467-025-59353-6
Abstract
Although vaccines are usually given intramuscularly, the intranasal delivery route may lead to better mucosal protection and limit the spread of respiratory virus while easing administration and improving vaccine acceptance. The challenge, however, is to achieve delivery across the selective epithelial cell barrier. Here we report on a subunit vaccine platform, in which the antigen is genetically fused to albumin to facilitate FcRn-mediated transport across the mucosal barrier in the presence of adjuvant. Intranasal delivery in conventional and transgenic mouse models induces both systemic and mucosal antigen-specific antibody responses that protect against challenge with SARS-CoV-2 or influenza A. When benchmarked against an intramuscularly administered mRNA vaccine or an intranasally administered antigen fused to an alternative carrier of similar size, only the albumin-based intranasal vaccine yields robust mucosal IgA antibody responses. Our results thus suggest that this needle-free, albumin-based vaccine platform may be suited for vaccination against respiratory pathogens.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.